HUE046631T2 - VEGFR-2 targetáló DNS vakcina kombinációs terápiára - Google Patents

VEGFR-2 targetáló DNS vakcina kombinációs terápiára

Info

Publication number
HUE046631T2
HUE046631T2 HUE16736381A HUE16736381A HUE046631T2 HU E046631 T2 HUE046631 T2 HU E046631T2 HU E16736381 A HUE16736381 A HU E16736381A HU E16736381 A HUE16736381 A HU E16736381A HU E046631 T2 HUE046631 T2 HU E046631T2
Authority
HU
Hungary
Prior art keywords
vegfr
combination therapy
dna vaccine
targeting dna
targeting
Prior art date
Application number
HUE16736381A
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of HUE046631T2 publication Critical patent/HUE046631T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HUE16736381A 2015-06-18 2016-06-16 VEGFR-2 targetáló DNS vakcina kombinációs terápiára HUE046631T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18

Publications (1)

Publication Number Publication Date
HUE046631T2 true HUE046631T2 (hu) 2020-03-30

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16736381A HUE046631T2 (hu) 2015-06-18 2016-06-16 VEGFR-2 targetáló DNS vakcina kombinációs terápiára

Country Status (20)

Country Link
US (2) US10905752B2 (hu)
EP (2) EP3626262B1 (hu)
JP (1) JP6947649B2 (hu)
KR (1) KR20180037948A (hu)
CN (1) CN107995868B (hu)
AU (1) AU2016278588B2 (hu)
BR (1) BR112017027378A2 (hu)
CA (1) CA2989247C (hu)
DK (1) DK3310379T3 (hu)
ES (1) ES2760699T3 (hu)
HK (1) HK1252435A1 (hu)
HU (1) HUE046631T2 (hu)
IL (1) IL256076A (hu)
LT (1) LT3310379T (hu)
MX (1) MX2017016183A (hu)
PL (1) PL3310379T3 (hu)
RU (1) RU2018101722A (hu)
SI (1) SI3310379T1 (hu)
WO (1) WO2016202459A1 (hu)
ZA (1) ZA201708439B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190082227A (ko) * 2016-11-04 2019-07-09 백심 아게 병용 요법용 wt1 표적화 dna 백신
BR112019016925A2 (pt) * 2017-02-17 2020-05-26 Vaximm Ag Cepa atenuada de salmonella
BR112019019251A2 (pt) * 2017-03-17 2020-04-28 Vaximm Ag cepa atenuada de salmonella
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
KR20220128638A (ko) * 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
DK2794849T3 (da) * 2011-12-22 2017-11-06 Vaximm Ag Fremgangsmåde til fremstilling af svækkede salmonellastammer med højt udbytte
RU2636348C2 (ru) * 2012-07-05 2017-11-22 Ваксимм Аг Днк-вакцина для применения у пациентов с раком поджелудочной железы
SG11201501850VA (en) * 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
SG11201506052PA (en) * 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
JP6416877B2 (ja) 2013-04-25 2018-10-31 バクシム アクチェンゲゼルシャフト ウィルムス腫瘍遺伝子wt1を標的とする癌免疫療法用のサルモネラベースのベクター
CA2932388A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
BR112019016925A2 (pt) * 2017-02-17 2020-05-26 Vaximm Ag Cepa atenuada de salmonella

Also Published As

Publication number Publication date
RU2018101722A3 (hu) 2019-12-10
CA2989247A1 (en) 2016-12-22
PL3310379T3 (pl) 2020-03-31
EP3626262A1 (en) 2020-03-25
WO2016202459A1 (en) 2016-12-22
JP2018517419A (ja) 2018-07-05
ES2760699T3 (es) 2020-05-14
LT3310379T (lt) 2019-12-27
CN107995868B (zh) 2021-07-13
HK1252435A1 (zh) 2019-05-24
JP6947649B2 (ja) 2021-10-13
SI3310379T1 (sl) 2020-02-28
CN107995868A (zh) 2018-05-04
CA2989247C (en) 2023-10-17
EP3626262B1 (en) 2024-10-23
IL256076A (en) 2018-01-31
ZA201708439B (en) 2021-05-26
DK3310379T3 (da) 2019-12-16
KR20180037948A (ko) 2018-04-13
US20180250345A1 (en) 2018-09-06
MX2017016183A (es) 2018-06-19
BR112017027378A2 (pt) 2018-08-28
AU2016278588B2 (en) 2022-03-31
EP3310379A1 (en) 2018-04-25
EP3310379B1 (en) 2019-11-06
AU2016278588A1 (en) 2017-12-21
US20210077605A1 (en) 2021-03-18
US10905752B2 (en) 2021-02-02
RU2018101722A (ru) 2019-07-18

Similar Documents

Publication Publication Date Title
IL284577A (en) Garden healing
IL260030A (en) Assemble a therapeutic neoepitope against cancer
ZA201904717B (en) Therapeutic hpv18 vaccines
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
HK1252435A1 (zh) 用於聯合治療的vegfr-2靶向dna疫苗
HK1215864A1 (zh) 用於埋線療法的套管
GB201407322D0 (en) Gene therapy
IL265684A (en) dna vaccine targeting wt1 for combination therapy
HK1246160A1 (zh) 用作治療性疫苗的納米粒子
IL266237A (en) Tolerogenic DNA composition
SI3162378T1 (sl) Nazalni sistem cepljenja za cepivo proti gripi